Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Challenges ZymoGenetics' Safety Claims

This article was originally published in The Pink Sheet Daily

Executive Summary

Agency takes issue with part of the better-than-bovine thrombin boast.

You may also be interested in...



ZymoGenetics Claims Competitor's Product Poses Serious Patient Safety Issue

As it tries to build market share for Recothrom, ZymoGenetics files Citizen's Petition asking FDA to remove its top competitor from the market.

ZymoGenetics Claims Competitor's Product Poses Serious Patient Safety Issue

As it tries to build market share for Recothrom, ZymoGenetics files Citizen's Petition asking FDA to remove its top competitor from the market.

Advertising Citations Reach Record High: Another Way To Regulate Pharma?

FDA's Division of Drug Marketing, Advertising and Communications has sent half of this year's citations for misleading advertising in the past month

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS067862

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel